<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54616">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395133</url>
  </required_header>
  <id_info>
    <org_study_id>R668-AD-1415</org_study_id>
    <secondary_id>2014-003384-38</secondary_id>
    <nct_id>NCT02395133</nct_id>
  </id_info>
  <brief_title>A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)</brief_title>
  <acronym>SOLO-Continue</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the ability of different dupilumab dose
      regimens, administered as monotherapy, to maintain the treatment response achieved after 16
      weeks of initial treatment with dupilumab monotherapy compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Investigator's Global Assessment (IGA) scores of 0 or 1 (clear or almost clear) at week 36</measure>
    <time_frame>At week 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with EASI-75 (Eczema Area and Severity Index â‰¥75%) improvement) at week 36 compared to the baseline EASI in the initial treatment study [NCT02277743 (R668-AD-1334) or NCT02277769 (R668-AD-1416)]</measure>
    <time_frame>At week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients whose Pruritus NRS increased by 3 or more points from baseline to week 36</measure>
    <time_frame>Baseline to week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">475</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received treatment regimen 1 of SC dupilumab in the initial treatment studies will be randomized to group 1 and receive 1 of 4 treatment regimens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received treatment regimen 2 of SC dupilumab in the initial treatment studies will be randomized to group 2 and receive 1 of 4 treatment regimens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>REGN668/SAR231893</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Must have completed the treatment phase in 1 of the two 16-week initial treatment
             studies (R668-AD-1334 or R668-AD-1416).

          2. Must have achieved at least 1 of the following 2 treatment success criteria:

             IGA = 0 or 1 (clear or almost clear) at week 16 OR EASI-75 (at least 75% reduction in
             EASI score from baseline to week 16)

          3. Must be willing and able to comply with clinic visits and study-related procedures

          4. Must provide signed informed consent

          5. Must be able to understand and complete study-related questionnaires

        Key Exclusion Criteria:

          1. Receipt of rescue medication for AD in the initial treatment study

          2. Any conditions that require permanent discontinuation of study treatment in either
             initial treatment study

          3. Planned or anticipated major surgical procedure during the patient's participation in
             this study

          4. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed
             during this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 23, 2016</lastchanged_date>
  <firstreceived_date>March 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
